Skip to content

Evaluation of Circulating Osteogenic Factors in Trauma Patients

Evaluation of Circulating Osteogenic Factors in Trauma Patients (BMP-9)

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01433536
Acronym
BMP-9
Enrollment
40
Registered
2011-09-14
Start date
2010-12-31
Completion date
2017-12-01
Last updated
2018-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cranial Trauma, Healthy, High Velocity Fracture, Spinal Trauma

Keywords

cranial trauma with or without high velocity fracture to inferior limb, spinal trauma with or without high velocity fracture to inferior limb, high velocity fracture to inferior limb

Brief summary

Bone fractures in traumatic brain-injured and spinal cord-injured patients often heal faster than in other patients. However, such patients are also occasionally prone to bone formation in soft tissues such as muscle. This process is called heterotopic ossification and tends to occur around joints. Patients with heterotopic ossification often suffer from complications such nerve compression, ankylosis, chronic pain, osteoporosis, and infections. Loss of movement can also interfere with function and the quality of life of patients already experiencing difficulties associated with their trauma. Positioning, transfers, and hygiene become difficult and even impossible, which worsens the loss of autonomy. Previous research has suggested that an osteoinductive factor (which has the capacity to induce the formation of bone) may be released into the bloodstream following a head or spinal cord injury. The investigators laboratory has shown that a growth factor called BMP-9, when injected into a damaged mouse muscle, has the ability to cause strong ossification in damaged muscle. The investigators would like to find out whether the levels of BMP-9 and/or its receptor (which is called ALK1) increase after traumatic brain and spinal cord injuries that occur at the same time as serious orthopaedic traumas. The main goal of the investigators study is thus to determine whether BMP-9 levels increase in the serum of trauma patients.

Interventions

None listed

Sponsors

Université de Sherbrooke
CollaboratorOTHER
Canadian Institutes of Health Research (CIHR)
CollaboratorOTHER_GOV
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* cranial trauma with Glasgow =\< 8 * spinal trauma with ASIA A, B, C * high-velocity fracture of femur, tibia, pelvis

Exclusion criteria

* brain dead * pathological fractures (cancer, osteoporosis) * blood transfusion received * pregnancy

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026